Spinal muscular atrophy results from genetic changes that impair the survival and function of lower motor neurons. The genes associated with this condition in the available data include PLEKHG5, UBA1, VAPB, DNAJB2, ASAH1, IGHMBP2, ATP7A, TRPV4, and SIGMAR1. Because multiple distinct genes have been identified in association with this condition, SMA represents a group of related disorders rather than a single uniform genetic entity, and the inheritance pattern can differ depending on the specific gene involved. Some forms are inherited in an autosomal recessive pattern, requiring altered copies from both parents, while other forms follow autosomal dominant or X-linked patterns. The precise molecular mechanism and inheritance data are not fully specified in the available information for this entry. Because several different genetic causes have been described, genetic counseling is strongly recommended to clarify the specific cause in each family and to discuss the implications for other family members.

Diagnosis of spinal muscular atrophy is established through molecular genetic testing, which identifies pathogenic variants in the genes associated with the condition, including PLEKHG5, UBA1, VAPB, DNAJB2, ASAH1, IGHMBP2, ATP7A, TRPV4, and SIGMAR1, among others. Testing may involve gene sequencing and deletion or duplication analysis, and the choice of testing strategy is guided by clinical presentation and family history. A thorough clinical evaluation, including assessment of muscle weakness, reflexes, and developmental history, supports the diagnostic process. Because many features of SMA can overlap with other neuromuscular conditions, molecular genetic testing is essential to confirm the diagnosis and distinguish it from conditions with similar presentations. Consultation with a neuromuscular specialist or clinical geneticist is recommended to guide appropriate testing.

Several FDA-approved treatments are available for spinal muscular atrophy. Approved therapies include nusinersen (Spinraza), risdiplam (Evrysdi), and onasemnogene abeparvovec (Zolgensma and Itvisma). These therapies represent important advances in modifying the course of the disease, and eligibility depends on individual factors including subtype, genetic findings, and clinical status, which should be discussed with the care team. Supportive care remains a foundational part of management and typically involves a multidisciplinary team addressing respiratory function, nutritional needs, orthopedic concerns, and physical and occupational therapy. Management is tailored to the individual based on the specific subtype and severity of symptoms. Additional therapies are under investigation in ongoing clinical trials. Patients should discuss treatment options with their healthcare team to determine which therapies may be appropriate for their specific situation. Genetic counseling is also recommended for affected individuals and their families.

The outlook for individuals with spinal muscular atrophy varies considerably depending on the subtype, the specific genetic cause, and the severity of muscle involvement at the time of diagnosis. Some individuals experience a slowly progressive course with relatively preserved function over many years, while others may face more significant challenges related to mobility, respiratory support, or swallowing. The availability of FDA-approved disease-modifying therapies has meaningfully changed the trajectory for many individuals, particularly those diagnosed early. With current standards of care, outcomes have improved for many people living with SMA, and active research continues to refine treatment approaches. The course is highly variable, and outcomes depend on individual factors including the specific genetic basis, age at diagnosis, and access to specialized care.

Spinal muscular atrophy is an active area of research, with numerous ongoing clinical trials investigating new and emerging therapeutic approaches. Studies are exploring novel mechanisms to support motor neuron survival, enhance muscle function, and expand treatment options across different subtypes and age groups. Several therapies are in early to advanced stages of clinical development, including approaches targeting distinct pathways involved in motor neuron health. Individuals interested in participating in clinical trials can search ClinicalTrials.gov or consult their care team about eligibility and available studies.